Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Elizabeth Cathcart-Rake"'
Autor:
Joseph S Ross, Molly Moore Jeffery, Lee Jones, Jessica D Ritchie, Cary P Gross, Jonas Paludo, Matthew Diamond, Vishal Bhatnagar, Amylou C Dueck, Kathryn J Ruddy, Gita Thanarajasingam, Abbie Brown, Elizabeth Cathcart-Rake, Louis Faust, Mallorie H Fiero, Brad Powers, Paul G Kluetz, Scott F Huntington, Brie N Noble, Sarah E Schellhorn, Michelle E Tarver
Publikováno v:
BMJ Open, Vol 14, Iss 1 (2024)
Introduction Accurate, patient-centred evaluation of physical function in patients with cancer can provide important information on the functional impacts experienced by patients both from the disease and its treatment. Increasingly, digital health t
Externí odkaz:
https://doaj.org/article/f14d933500d0462891582c165cec6a06
Autor:
Emily Brugioni, Elizabeth Cathcart-Rake, Janie Metsker, Elizabeth Gustafson, Lindsey Douglass, Timothy J. Pluard
Publikováno v:
Clinical Breast Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f80b81addb7ee686d4452ea3098a7f24
https://doi.org/10.1016/j.clbc.2023.04.006
https://doi.org/10.1016/j.clbc.2023.04.006
Autor:
Gita Thanarajasingam, Paul Kluetz, Vishal Bhatnagar, Abbie Brown, Elizabeth Cathcart-Rake, Matthew Diamond, Louis Faust, Mallorie Fiero, Scott Huntington, Molly Moore Jeffery, Lee Jones, Brie Noble, Jonas Paludo, Brad Powers, Joseph S. Ross, Jessica Ritchie, Kathryn Ruddy, Sarah Schellhorn, Michelle Tarver, Amylou Dueck, Cary Gross
Publikováno v:
medRxiv
Introduction Accurate, patient-centered evaluation of physical function in patients with cancer can provide important information on the functional impacts experienced by patients both from the disease and its treatment. Increasingly, digital health
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc26c413331b45815a4442ffa72a0f5
https://doi.org/10.1101/2023.03.08.23286924
https://doi.org/10.1101/2023.03.08.23286924
Autor:
Elizabeth Cathcart-Rake, Charles L Loprinzi, Fergus Couch, Janet Olson, Brittany Dulmage, Maryam Lustberg, Nicole Larson, Kathryn J Ruddy
Publikováno v:
Cancer Research. 82:P4-10
Background: Eyebrow and eyelash loss are widely recognized as consequences of some chemotherapies, but prevalence and predictors are understudied. The purpose of this study was to evaluate real world experiences of eyebrow and eyelash loss during tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ef06706808b2c240b2a2d873861d4cc
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-11
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-11
Autor:
Elizabeth Cathcart-Rake, Charles L Loprinzi, Janet E Olson, Fergus Couch, Brittany Dulmage, Maryam Lustberg, Nicole Larson, Kathryn J Ruddy
Publikováno v:
Cancer Research. 82:P4-10
Funding Source: Institutional funds at Mayo Clinic. Background: While alopecia is a common and distressing acute side effect of chemotherapy, chronic hair thinning is also reported by some survivors during endocrine therapy. The purpose of the curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa2690d1b991a7a57af1c5b97e9dc804
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-17
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-17
Autor:
Lucy Rose, Maryam Lustberg, Kathryn J. Ruddy, Elizabeth Cathcart-Rake, Charles Loprinzi, Brittany Dulmage
Publikováno v:
Supportive Care in Cancer. 31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5a85ebc1cc3e76af9a31ce3307645df
https://doi.org/10.1007/s00520-023-07634-5
https://doi.org/10.1007/s00520-023-07634-5
Autor:
Nusrat Jahan, Jodi Taraba, Karthik V. Giridhar, Roberto A. Leon-Ferre, Amye J. Tevaarwerk, Elizabeth Cathcart-Rake, Ciara C. O’Sullivan, Prema Peethambaram, Timothy J. Hobday, Kathryn Ruddy, Lida A. Mina, Pooja Advani, Felipe Batalini, Matthew P. Goetz, Tufia C. Haddad, Fergus J. Couch, Siddhartha Yadav
Publikováno v:
Cancer Research. 83:P4-01
Background: Two poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) are currently FDA-approved for the treatment of HER2-negative metastatic breast cancer (MBC) in carriers of germline pathogenic variants (PVs) in BRCA1 or BRCA2 (BRCA1/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47f55de786e6ac1644ca85093aa8726c
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-22
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-22